Coverage is subject to the specific terms of the member's benefit plan.
Federal Employee Program members (FEP) should check with their Retail Pharmacy Program to determine if prior approval is required by calling the Retail Pharmacy Program at 1-800-624-5060 (TTY: 1-800-624-5077). FEP members can also obtain the list through the www.fepblue.org website.
Elranatamab-bcmm (Elrexfio) may be considered medically necessary for the following:
- For the treatment of adult individuals 18 years of age or older with relapsed or refractory multiple myeloma who have received at least four (4) prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody; or
Elranatamab-bcmm (Elrexfio) may be considered medically necessary for treatment of any of the current category 1 or 2A NCCN recommendations.
The use of elranatamab-bcmm (Elrexfio) for all other indications not listed in this policy is considered experimental/investigational and therefore non-covered because the safety and/or effectiveness cannot be established by the available published peer-reviewed literature.